Pay in 4 interest-free payments of $6.04 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
When in doubt, choose the smallest syringe that fits your dose
(Nasdaq: GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pioneering pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced positive 6-month results from its open-label REVEAL-1 Cohort
Emerging data also point to benefits in conditions such as obstructive sleep apnea (OSA) and chronic kidney disease, including tirzepatide for moderate-to-severe OSA in adults with obesity and semaglutide for reducing kidney and cardiovascular risk in adults with CKD and T2D
US$ 27.34
US$ 24.14
US$ 28.49
US$ 26.33
US$ 24.35
